271 results on '"Kanfer E"'
Search Results
2. High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMT
3. High-dose chemotherapy with autologous stem cell transplants in adult primary non-seminoma mediastinal germ-cell tumors. A report from the Cellular Therapy and Immunobiology working party of the EBMT
4. Salvage high-dose chemotherapy in female patients with relapsed/refractory germ-cell tumors: a retrospective analysis of the European Group for Blood and Marrow Transplantation (EBMT)
5. Analysis of hematopoietic recovery after autologous transplantation as method of quality control for long-term progenitor cell cryopreservation
6. Outcome and prognostic factors in patients with mantle-cell lymphoma relapsing after autologous stem-cell transplantation: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT)
7. Autologous hematopoietic stem cell transplantation for intravascular large B-cell lymphoma: the European Society for Blood and Marrow Transplantation experience
8. Prognostic impact of progression to induction chemotherapy and prior paclitaxel therapy in patients with germ cell tumors receiving salvage high-dose chemotherapy in the last 10 years: a study of the European Society for Blood and Marrow Transplantation Solid Tumors Working Party
9. Outcomes of autologous stem cell transplantation (ASCT) in patients with relapsed/refractory HIV-associated lymphoma
10. Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party
11. Development of acute graft-versus-host disease post allogeneic stem cell transplantation results in significant episodes of recurrent and prolonged hospitalisations which are with associated a significant economic burden to stem cell transplant units: AB30
12. The 10-year clinical outcomes of reduced-intensity allogeneic stem cell transplantation for patients with advanced-stage mycosis fungoides and Sézary syndrome: O06
13. Escalating-dose HLA-mismatched DLI is safe for the treatment of leukaemia relapse following alemtuzumab-based myeloablative allo-SCT
14. Hypogammaglobulinaemia after rituximab treatment—incidence and outcomes
15. HIGH DOSE ETOPOSIDE/GCSF IS A SAFE AND EFFECTIVE MOBILIZATION REGIMEN IN MULTIPLE MYELOMA: A SINGLE-INSTITUTION EXPERIENCE: PH-AB225
16. Response to donor lymphocyte infusions for chronic myeloid leukemia is dose-dependent: the importance of escalating the cell dose to maximize therapeutic efficacy
17. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin's lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre
18. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients
19. Monitoring patients in complete cytogenetic remission after treatment of CML in chronic phase with imatinib: patterns of residual leukaemia and prognostic factors for cytogenetic relapse
20. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma
21. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients
22. Identification of prognostic factors predicting outcome in Hodgkinʼs lymphoma patients relapsing after autologous stem cell transplantation†
23. Donor KIR2DS2/DL2 genotype status is associated with an increased incidence of severe acute graft-versus-host disease following myeloablative haematopoeitic stem cell transplantation: O160
24. Immune haemolytic anaemia following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia: association with leukaemic relapse and treatment with donor lymphocyte infusions
25. A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation
26. A comparison of prophylactic vs pre-emptive ganciclovir to prevent cytomegalovirus disease after T-depleted volunteer unrelated donor bone marrow transplantation
27. KIR genotype is associated with progression free and overall survival following autologous stem cell transplantation for multiple myeloma: 38
28. High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial
29. Ethnicity and Myeloma: Experience of a Large UK Stem Cell Transplantation Center: A537
30. CD34 counts to predict the adequate collection of peripheral blood progenitor cells
31. A retrospective analysis of sexual function, fertility and endocrine status in male long-term survivors of allografts for haematological malignancy
32. Secondary malignancies in recipients of allografts for chronic myeloid leukaemia in chronic phase using HLA-matched sibling or volunteer donors
33. Absence of cyclin-D2 and Bcl-2 expression within the germinal centre type of diffuse large B-cell lymphoma identifies a very good prognostic subgroup of patients
34. Cardiovascular risk factors in long-term survivors of allogeneic SCT for CML
35. Secondary malignancies in recipients of allogeneic stem cell transplantation for CML in chronic phase using HLA-identical sibling or HLA-compatible unrelated donors
36. The combination of sRANKL/osteoprotegerin ratio, beta2-microglobulin and CRP predicts survival in patients with multiple myeloma post autologous stem cell transplantation
37. Cytomegalovirus seropositivity adversely influences outcome after T-depleted unrelated donor transplant in patients with chronic myeloid leukaemia: the case for tailored graft-versus-host disease prophylaxis
38. High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience
39. CD34+ -selected peripheral blood progenitor cell transplantation in patients with multiple myeloma: tumour cell contamination and outcome
40. High-dose chemotherapy (HDCT) for recurrent ovarian germ cell tumours (OGCT): A single centre experience
41. DONOR LYMPHOCYTE INFUSIONS INDUCE DURABLE RESPONSES IN PATIENTS WITH FOLLICULAR, MANTLE AND T CELL LYMPHOMAS RELAPSING AFTER AN ALLOSCT. AN EBMT-LWP STUDY
42. The results of treatment with high-dose chemotherapy and peripheral blood stem cell support for gestational trophoblastic neoplasia
43. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018
44. INTERLEUKIN-2 MAY INDUCE COMPLETE REMISSION IN PATIENTS WHO RESPOND ONLY PARTIALLY TO DONOR LYMPHOCYTE INFUSION (DLI) FOR RELAPSE FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION
45. Authors' reply
46. Haemoglobin concentration and erythrocyte sedimentation rate in primary care patients
47. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia
48. Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: an international, multicentre, randomised, double-blind, placebo-controlled trial
49. Unusual Association of Aplastic Anemia and Lymphoid Neoplasm: A Survey of the Severe Aplastic Anemia Working Party of the EBMT
50. Development of acute graft-versus-host disease post allogeneic stem cell transplantation results in significant episodes of recurrent and prolonged hospitalisations which are with associated a significant economic burden to stem cell transplant units
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.